Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
CorMedix Inc Market Cap
From what 1 stock analysts predict, the share price for CorMedix Inc (CRMD) might increase by 123.21% in the next year. This is based on a 12-month average estimation for CRMD. Price targets go from $9 to $19. The majority of stock analysts believe CRMD is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
CorMedix Inc has a total of 1 Wall St Analyst ratings. There are 1 buy ratings, 0 ratings, and 0 sell ratings. Since most analysts have a buy consensus rating, the expectation is that CorMedix Inc will outperform the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.
These are the latest 20 analyst ratings of CRMD.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Brandon Folkes Rodman & Renshaw | Buy | $13 | Initiates | Aug 26, 2024 |
| Gregory Renza RBC Capital | Outperform | $9 | Reiterates | Aug 15, 2024 |
| Serge Belanger Needham | Buy | $10 | Reiterates | Aug 15, 2024 |
| Joon Lee Truist Securities | Buy | $12 | Maintains | Jul 25, 2024 |
| Serge Belanger Needham | Buy | $10 | Reiterates | Jun 19, 2024 |
| Serge Belanger Needham | Buy | $10 | Reiterates | May 13, 2024 |
| Jason Butler JMP Securities | Market Outperform | $19 | Reiterates | Apr 9, 2024 |
| Serge Belanger Needham | Buy | $10 | Reiterates | Apr 9, 2024 |
| Gregory Renza RBC Capital | Outperform | $9 | Maintains | Mar 13, 2024 |
| Serge Belanger Needham | Buy | $10 | Maintains | Mar 12, 2024 |
| Joon Lee Truist Securities | Buy | $14 | Maintains | Jan 31, 2024 |
| Gregory Renza RBC Capital | Outperform | $10 | Maintains | Nov 15, 2023 |
| Joon Lee Truist Securities | Buy | $18 | Reiterates | Nov 15, 2023 |
| Serge Belanger Needham | Buy | $10 | Maintains | Nov 15, 2023 |
| Jason Butler JMP Securities | Market Outperform | $19 | Reiterates | Nov 15, 2023 |
| Gregory Renza RBC Capital | Outperform | $6 | Initiates | Aug 10, 2023 |
| Serge Belanger Needham | Buy | $12 | Maintains | Aug 8, 2023 |
| Serge Belanger Needham | Buy | $13 | Reiterates | Jun 21, 2023 |
| Jason Butler JMP Securities | Market Outperform | $19 | Maintains | May 19, 2023 |
| Serge Belanger Needham | Buy | $13 | Reiterates | May 16, 2023 |
When did it IPO
N/A
Staff Count
82
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Mr. Joseph Todisco MBA
Market Cap
$344.7M
In 2023, CRMD generated $0 in revenue, which was a decrease of -100.00% from the previous year. This can be seen as a signal that CRMD's business is declining, and its share price could be worth less in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Tue, 20 Aug 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - The mean of analysts' price targets for CorMedix (CRMD) points to a 142.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Wed, 14 Aug 2024
Sentiment - NEUTRAL
Source - Seeking Alpha
Summary - CorMedix Inc. (NASDAQ:CRMD ) Q2 2024 Earnings Conference Call August 14, 2024 8:30 AM ET Company Participants Dan Ferry - LifeSci Advisors Joe Todisco - CEO Matt David - EVP and CFO Liz Hurlburt - EVP and Chief Clinical Strategy and Operations Officer Conference Call Participants Anish Nikhanj - RBC Capital Markets Jason Butler - Citizens JMP Les Sulewski - Truist John Juco - Needham & Company Operator Good day, and welcome to the CorMedix Inc. Second Quarter 2024 Financial Results Conference Call. [Operator Instructions] Please note, this event is being recorded.
Wed, 14 Aug 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - BERKELEY HEIGHTS, N.J., Aug. 14, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced financial results for the second quarter and six months ended June 30, 2024 and provided an update on its business.
Wed, 14 Aug 2024
Sentiment - NEGATIVE
Source - Zacks Investment Research
Summary - CorMedix (CRMD) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to loss of $0.25 per share a year ago.
Wed, 07 Aug 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - BERKELEY HEIGHTS, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that it will report its financial results for the second quarter ended June 30, 2024, before the market opens on Wednesday, August 14, 2024, and will host a corporate update conference call at 8:30am Eastern Time.
Wed, 03 Jul 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - BERKELEY HEIGHTS, N.J., July 03, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing therapeutic products for life-threatening diseases and conditions, today announced that it has commenced commercialization of DefenCath® (taurolidine and heparin) to outpatient dialysis centers and vascular access clinics where patients receive outpatient dialysis and catheter placement services. The outpatient launch coincides with the effective date of July 1st for outpatient reimbursement of DefenCath as directed by the Center for Medicare & Medicaid Services (CMS).
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
